Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE: Believable
INDICATION: plaque psoriasis Psoriasic arthritis Crohn's disease Ulcerative colitis
DATE: 05/01/2024
STATUS: Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE